Skip to main content
05/09/2023 - 14:21

Discussing innovative and novel cardioprotective therapies

Discussing innovative and novel cardioprotective therapies - Available at University of Iceland

Around 50 research scientist and specialists in the field of cardiovascular disease attend a conference on campus from 6 to 8 September where they will discuss new ways to reduce the impact of these diseases on the heart. Academics at the University of Iceland organise the conference and give talks.

The conference is under the auspices of the research project IMproving Preclinical Assessment of Cardioprotective Therapies" (IMPACT), supported by the European Cooperation in Science and Technology (COST). COST supports European collaboration in science, innovation and technology in order to build bridges between researchers and industry, thus facilitating the development of new solutions benefitting society at large.

The IMPACT-project revolves around further research on  the translation of cardioprotective therapies in the wake of Acute myocardial infarction into the clinical setting. Acute myocardial infarction, and the heart failure that often follows, are among the leading causes of death and disability in Europe and worldwide. It is thus imperative to find new ways to protect the heart muscle from acute ischaemia-reperfusion injury, in the wake of such trauma.

The local organiser and host  is Georgios Kararigas, professor of physiology at the University of Iceland's Faculty of Medicine, and the conference takes place in the deCode building at Sturlugata 8. Also taking part in the conference are research scientists from the University of Iceland, deCode, Landspítali University Hospital, and the Icelandic Heart Association. The talks tackle  subjects such as genetics insights into cardiovascular disease, the use of AI in the practice of cardiology, and the current findings of the IMPACT project. 

The conference is open to all interested and registration takes place online.

The conference programme is available here.